APP and Alzheimer disease: Even if the associations between early stages of AD, progressive cognitive decline, reductions of APP ratio or alterations of secretases activity were demonstrated it is still uncertain if these elements can serve either as reliable biomarkers for preclinical stage of AD or as therapeutic targets.